Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Cyclacel Pharmaceuticals ( (CYCC) ) is now available.
On June 3, 2025, Cyclacel Pharmaceuticals announced that it regained compliance with the Nasdaq Minimum Bid Price Requirement, following a previous notice on December 6, 2024, regarding non-compliance. The company achieved this by maintaining a closing bid price of $1.00 or greater for 15 consecutive business days, closing the matter with Nasdaq.
The most recent analyst rating on (CYCC) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Cyclacel Pharmaceuticals stock, see the CYCC Stock Forecast page.
Spark’s Take on CYCC Stock
According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on CYCC stock, click here.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines. The company specializes in cell cycle, transcriptional regulation, and mitosis biology, with a notable program being the anti-mitotic plogosertib, a PLK1 inhibitor, targeting both solid tumors and hematological malignancies.
Average Trading Volume: 199,251
Technical Sentiment Signal: Strong Sell
Current Market Cap: $36.53M
Learn more about CYCC stock on TipRanks’ Stock Analysis page.